Literature DB >> 3262460

Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1.

S J Hopkins1, M Humphreys, M I Jayson.   

Abstract

Using a sensitive IL-1-dependent T cell clone we estimated interleukin 1 (IL-1)-like activity in a variety of synovial fluids (SF). Although we demonstrate that SF contains potent inhibitors of endogenous and exogenous IL-1 we were able to estimate that samples from rheumatoid arthritis, osteoarthritis and other arthritides contain the equivalent of tens or hundreds of picograms of IL-1 per millilitre, when compared to a standard IL-1 preparation. Although there was some correlation between these results and those obtained using a radio-immunoassay (RIA) for IL-1 beta, the RIA indicated that IL-1 was present in the nanogram range. The results suggest that the importance of inhibitors of IL-1 in SF merits particular attention and that it is also important to consider the bioactivity of cytokines which may be detected by physical methods.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262460      PMCID: PMC1541559     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  Induction of receptors for interleukin 2 requires T cell Ag:Ia receptor crosslinking and interleukin 1.

Authors:  J Kaye; C A Janeway
Journal:  Lymphokine Res       Date:  1984

2.  Isolation of an interleukin-1-like factor from human joint effusions.

Authors:  D D Wood; E J Ihrie; C A Dinarello; P L Cohen
Journal:  Arthritis Rheum       Date:  1983-08

Review 3.  Cytokines and other mediators in rheumatoid arthritis.

Authors:  J M Dayer; S Demczuk
Journal:  Springer Semin Immunopathol       Date:  1984

4.  DNA synthesis-potentiating activity on mouse thymocytes of synovial fluid of rheumatoid arthritis patients.

Authors:  K Ise; S Nakamura; S Ohkawara; M Yoshinaga
Journal:  Acta Pathol Jpn       Date:  1982-05

5.  Establishment and characterization of a human acute monocytic leukemia cell line (THP-1).

Authors:  S Tsuchiya; M Yamabe; Y Yamaguchi; Y Kobayashi; T Konno; K Tada
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

6.  Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis.

Authors:  A Fontana; H Hengartner; E Weber; K Fehr; P J Grob; G Cohen
Journal:  Rheumatol Int       Date:  1982       Impact factor: 2.631

7.  Demonstration of a circulating suppressor factor of thymocyte proliferation during endotoxin fever in humans.

Authors:  C A Dinarello; L J Rosenwasser; S M Wolff
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

8.  Cytokines and the chronic inflammation of rheumatic disease. I. The presence of interleukin-1 in synovial fluids.

Authors:  A M Nouri; G S Panayi; S M Goodman
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

9.  Characterization of a human interleukin 1 inhibitor.

Authors:  Z Liao; A Haimovitz; Y Chen; J Chan; D L Rosenstreich
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

10.  Modulation of connective tissue metabolism by partially purified human interleukin 1.

Authors:  H J Richardson; P R Elford; R M Sharrard; J E Meats; R G Russell
Journal:  Cell Immunol       Date:  1985-01       Impact factor: 4.868

View more
  39 in total

Review 1.  Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis.

Authors:  B Kirkham
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

2.  Human rheumatoid synovial cell stimulation by the membrane attack complex and other pore-forming toxins in vitro: the role of calcium in cell activation.

Authors:  R H Daniels; B D Williams; B P Morgan
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

3.  Inhibition of matrix metalloproteinases enhances in vitro repair of the meniscus.

Authors:  Amy L McNulty; J Brice Weinberg; Farshid Guilak
Journal:  Clin Orthop Relat Res       Date:  2008-10-31       Impact factor: 4.176

4.  Selective and non-selective metalloproteinase inhibitors reduce IL-1-induced cartilage degradation and loss of mechanical properties.

Authors:  Christopher G Wilson; Ashley W Palmer; Fengrong Zuo; Elsie Eugui; Stacy Wilson; Rebecca Mackenzie; John D Sandy; Marc E Levenston
Journal:  Matrix Biol       Date:  2006-11-11       Impact factor: 11.583

Review 5.  Vascular endothelium, cytokines, and the pathogenesis of inflammatory synovitis.

Authors:  A Kaul; D R Blake; J D Pearson
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

6.  The effect of gold sodium thiomalate and auranofin on lipopolysaccharide-induced interleukin-1 production by blood monocytes in vitro: variation in healthy subjects and patients with arthritis.

Authors:  V A Danis; A J Kulesz; D S Nelson; P M Brooks
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

Review 7.  The roles of catabolic factors in the development of osteoarthritis.

Authors:  Dominick J Blasioli; David L Kaplan
Journal:  Tissue Eng Part B Rev       Date:  2013-12-11       Impact factor: 6.389

Review 8.  Articular cartilage destruction in experimental inflammatory arthritis: insulin-like growth factor-1 regulation of proteoglycan metabolism in chondrocytes.

Authors:  P J Verschure; C J Van Noorden; J Van Marle; W B Van den Berg
Journal:  Histochem J       Date:  1996-12

9.  Protection from interleukin 1 induced destruction of articular cartilage by transforming growth factor beta: studies in anatomically intact cartilage in vitro and in vivo.

Authors:  H M van Beuningen; P M van der Kraan; O J Arntz; W B van den Berg
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

10.  Synovial fluid concentrations and relative potency of interleukin-1 alpha and beta in cartilage and meniscus degradation.

Authors:  Amy L McNulty; Nicole E Rothfusz; Holly A Leddy; Farshid Guilak
Journal:  J Orthop Res       Date:  2013-03-11       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.